Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | G6PD | P11413 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranimustine SCHEMBL1650173 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL10079210 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL11757182 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL8333 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL15474340 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL22595035 | 1.00 | ALDH1A1 (0.46) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL5506489 | 0.90 | ADRA2A (0.58) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| SCHEMBL17524415 | 0.89 | CA1 (0.44) | CA1CA2CA9G6PDMMP9 | |
| Ranimustine SCHEMBL2678774 | 0.89 | PYGB (0.44) | ALDH1A1BLMPMP22MEN1ABCB11 | |
| Ranimustine SCHEMBL4197596 | 0.89 | ALDH1A1 (0.37) | ALDH1A1BLMPMP22MEN1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838469-B2 | Pharmaceutical composition that exhibits reduced side-effects comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoxime and a pyrimidine derivative with known antitumor activity | N-GENE RESEARCH LABORATORIES INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-6720337-B2 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxlmic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6656955-B2 | Side effect reduction; synergistic mixture | N-GENE RESEARCH LABORATORIES, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-0993304-B1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N GENE RES LAB INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2003-03-13 | — | — | US | disclosed |
| US-6440998-B1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050345-A1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDGF, CA7 | ALDH1A1 219/4885BLM 4035/4885PMP22 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.